145 related articles for article (PubMed ID: 1717600)
1. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.
Ghetie V; Thorpe P; Ghetie MA; Knowles P; Uhr JW; Vitetta ES
J Immunol Methods; 1991 Sep; 142(2):223-30. PubMed ID: 1717600
[TBL] [Abstract][Full Text] [Related]
2. Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain.
Ghetie V; Ghetie MA; Uhr JW; Vitetta ES
J Immunol Methods; 1988 Sep; 112(2):267-77. PubMed ID: 3262139
[TBL] [Abstract][Full Text] [Related]
3. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
Ghetie V; Swindell E; Uhr JW; Vitetta ES
J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
5. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
[TBL] [Abstract][Full Text] [Related]
6. Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain.
Ghetie V; Till MA; Ghetie MA; Uhr JW; Vitetta ES
J Immunol Methods; 1990 Jan; 126(1):135-41. PubMed ID: 2303721
[TBL] [Abstract][Full Text] [Related]
7. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
Amlot PL; Stone MJ; Cunningham D; Fay J; Newman J; Collins R; May R; McCarthy M; Richardson J; Ghetie V
Blood; 1993 Nov; 82(9):2624-33. PubMed ID: 8219217
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM
Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133
[TBL] [Abstract][Full Text] [Related]
11. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
12. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
Ghetie V; Engert A; Schnell R; Vitetta ES
Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
[TBL] [Abstract][Full Text] [Related]
13. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
[TBL] [Abstract][Full Text] [Related]
15. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
[TBL] [Abstract][Full Text] [Related]
16. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Senderowicz AM; Vitetta E; Headlee D; Ghetie V; Uhr JW; Figg WD; Lush RM; Stetler-Stevenson M; Kershaw G; Kingma DW; Jaffe ES; Sausville EA
Ann Intern Med; 1997 Jun; 126(11):882-5. PubMed ID: 9163289
[No Abstract] [Full Text] [Related]
17. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
18. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
[TBL] [Abstract][Full Text] [Related]
19. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
20. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
Pop LM; Liu X; Ghetie V; Vitetta ES
Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
